Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

story of the week

Published in Metastatic Breast Cancer

Journal Scan / Research · September 30, 2024

Patient-Reported Outcomes of Capivasertib Plus Fulvestrant Therapy for HR+/HER2− Advanced Breast Cancer

The Lancet Oncology

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Not a member?

Join for free

Disclosure statements are available on the authors' profiles:

Lillie Shockney RN, BS, MAS, HON-ONN-CG

The Lancet Oncology

Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial

Lancet Oncol 2024 Sep 01;25(9)1231-1244, M Oliveira, HS Rugo, SJ Howell, F Dalenc, J Cortes, HL Gomez, X Hu, M Toi, K Jhaveri, P Krivorotko, S Loibl, S Morales Murillo, M Okera, Z Nowecki, YH Park, JH Sohn, E Tokunaga, S Yousef, L Zhukova, M Fulford, H Andrews, I Wadsworth, C D'Cruz, NC Turner

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Metastatic Breast Cancer

Patient-Reported Outcomes of Capivasertib Plus Fulvestrant Therapy for HR+/HER2− Advanced Breast Cancer

Additional Info

Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial

Further Reading

Pharmacokinetics and Pharmacogenomics of Ribociclib in Black Patients With Metastatic Breast Cancer

Efficacy and Safety of Elacestrant in ER+/HER2− MBC With ESR1-Mutated Tumors Based on Prior Duration of Endocrine Therapy Plus CDK4/6i and in Clinical Subgroups

Acquired Gene Alterations in Patients Treated With Endocrine Therapy ± Ribociclib Using Baseline and End-of-Treatment ctDNA Samples

Safety of Inavolisib Plus Palbociclib and Endocrine Therapy for PIK3CA-Mutated, HR+/HER2− Advanced or Metastatic Breast Cancer

Outcomes of Pembrolizumab Plus Chemotherapy in Asian Patients With Advanced TNBC

Prophylactic Efficacy of Olanzapine-Based Therapy for Trastuzumab Deruxtecan–Associated Nausea and Vomiting in Patients With HER2-Positive or HER2-Low Breast Cancer

Outcomes of Imlunestrant, an Oral SERD, as Monotherapy and in Combination With Targeted Therapy in ER+/HER2− Advanced Breast Cancer

Patient-Reported Outcomes of Capivasertib Plus Fulvestrant Therapy for HR+/HER2− Advanced Breast Cancer

HR+ Metastatic Breast Cancer Survival Outcomes Before and After CDK4/6 Inhibitor Introduction in the US

Analysis of HER2 Expression Changes From Primary Breast Tumors to Brain Metastases and the Impact of HER2-Low Expression on Overall Survival

Olaparib Plus Trastuzumab for HER2-Positive Advanced Breast Cancer With Germline BRCA1/2 Mutations

Recently Updated